First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial 5. November 2020 Staehler, M, Panic, A, Goebell, PJ, Merling, M, Potthoff, K, Herrmann, E, de Geeter, P, Vannier, C, Hogrefe, C, Marschner, N, Grünwald, V, 2020. Int J Cancer. 2020;1-11. Abstract Patient, nurse and physician preferences: Final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or On-body injector (OBI) in cancer patients M. Metz, D. Semsek, G. Rogmans, U. Hutzschenreuter, T. Fietz, J. Harde, S. Zacharias, C. Hielscher, A. Lorenz, M.-O. Zahn, D. Guth, S. Grebhardt, C. Weiterlesen What affects the choice of first-line treatment for hormone-receptor-positive, HER2-negative advanced breast cancer? Data from the German research platform OPAL A. Welt, M. Thill, E. Stickeler, M.-O. Zahn, A. Nusch, M. Zaiss, U. Neef, S. Fruehauf, R. Buss-Steidle, V. Hagen, M. Chiabudini, L. Kruggel, M. Weiterlesen